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Abstract
The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering
with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic
strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-
2 against a range spectrum of human B-cell lines, fresh patient samples and animal xenograft models.
Multiple cytochemical and molecular approaches such as acridine orange/ethidium bromide assay
for apoptosis, co-immunoprecipitation of complexes and western blot analysis, caspase
luminescent activity assay and apoptotic DNA fragmentation assay were used to demonstrate the
effect of TW-37 on different B-cell lines, patient derived samples, as well as in animal xenograft
models. Nanomolar concentrations of TW-37 were able to induce apoptosis in both fresh samples
and established cell lines with IC50 in most cases of 165–320 nM. Apoptosis was independent of
proliferative status or pathological classification of B-cell tumor. TW-37 was able to block Bim-Bcl-
XL and Bim-Mcl-1 heterodimerization and induced apoptosis via activation of caspases -9, -3, PARP
and DNA fragmentation. TW-37 administered to tumor-bearing SCID mice led to significant tumor
growth inhibition (T/C), tumor growth delay (T-C) and Log10kill, when used at its maximum
tolerated dose (40 mg/kg × 3 days) via tail vein. TW-37 failed to induce changes in the Bcl-2
proteins levels suggesting that assessment of baseline Bcl-2 family proteins can be used to predict
response to the drug. These findings indicate activity of TW-37 across the spectrum of human B-
cell tumors and support the concept of targeting the Bcl-2 system as a therapeutic strategy
regardless of the stage of B-cell differentiation.
Background
Lymphoid cancers are common in the US. They include a
heterogeneous group of diseases spanning the full spec-
trum of both T- and B- cell differentiation stages. Non-
Hodgkin's lymphoma (NHL), the most common among
these disorders, is the 5th and 6th most common cancer
among the male and female US population, respectively
[1]. When combined with other lymphoid cancers like
multiple myeloma (MM), acute lymphoblastic leukemia
(ALL) and chronic lymphocytic leukemia (CLL), these dis-
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eases form more than 7% of all cancers in the US with
more than 103,000 cases estimated to be diagnosed in
2007 [1].
There are different ways of classifying malignant lym-
phoid disorders based on morphology, clinical behavior,
cell lineage, immunophenotypes, genetic abnormalities
or a combination of these features [2-4]. We have chosen
to catalogue malignant B-lymphoid disorders according
to the state of differentiation they represent and estab-
lished a number of cell lines representing them [5].
According to this schema, B-cell tumors are believed to
represent discrete stages of B-cell differentiation from the
most immature (like ALL) to the most mature (like MM
and Waldenstrom's Macroglobulinemia [WM]) stages.
Disorders of the early stages (ALL, high grade NHL) are
curable with chemotherapy that is the mainstay of treat-
ment, whereas tumors of the more mature stages (like low
grade NHL, CLL, WM, MM) remain incurable [6]. At the
molecular genetic level, most of these disorders are char-
acterized by very well defined, specific non-random
abnormalities that are potential targets for new therapy.
Among the most common molecular genetic abnormali-
ties in lymphoid tumors are those involving Bcl-2 and
other apoptosis-regulating molecules [7-9].
Recent research efforts have yielded a number of synthetic
small molecules capable of interfering with cellular path-
ways [10-13]. One such small molecule inhibitor (SMI) is
TW-37 [14]. This compound binds with high affinity to
the hydrophobic groove found in the multidomain anti-
apoptotic Bcl-2 family proteins; this groove is naturally
the site for interaction with BH3 alpha helix in the BH3-
only pro-apoptotic proteins. Drug binding is thought to
block the anti-apoptotic proteins from heterodimerizing
with the pro-apoptotic members of the Bcl-2 family (Bad,
Bid, Bim) or may produce conformational changes that
disable the anti-apoptotic members. It is well known that
over expression of anti-apoptotic Bcl-2 proteins leads to
apoptosis-resistance and is believed to be a major reason
for treatment failure in lymphoid tumors [15-19]. In this
report, we show that exposure of a variety of B-cell tumor
cells to TW-37 is sufficient to inhibit growth and induce
apoptosis. The study mechanistically demonstrates the
clinical relevance of the Bcl-2 system as therapeutic target
in these tumors.
Materials and methods
TW-37
Design, synthesis, purification, and chemical characteriza-
tion of TW-37 N-[(2-tert-butyl-benzenesulfonyl)-phenyl]-
2,3,4-trihydroxy-5-(2-isopropyl-benzyl)-benzamide is
described in detail in ref [14]; in the inactive congener
TW-37a, all three hydroxyl groups in the polyphenolic
ring have been substituted with a methyl group, resulting
in a 100-fold loss of binding.
Cell lines and patient-derived primary lymphocytes
The acute lymphoblastic leukemia (WSU-pre-B-ALL), dif-
fuse large cell lymphoma cell line (WSU-DLCL2), follicu-
lar small cleaved cell lymphoma (WSU-FSCCL) and
Waldenstrom's macroglobulinemia (WSU-WM) cell lines
were established in our laboratory at the Wayne State Uni-
versity School of Medicine [20-23]. The WSU-pre-B-ALL
cell line is CD10+, CD19+, CD20+, TdT+; the WSU-
DLCL2 and WSU-FSCCL are both mature (SIg+), CD20+
cell lines. The WSU-WM cell line is IgM-secreting cell line.
Fresh peripheral blood samples were obtained from
patients with active chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL) or marginal zone
lymphoma (MZL) in leukemic phase under IRB-approved
protocol and used to assess the TW-37 cytotoxic effect on
primary lymphoma cells. The CLL/SLL cells expressed
CD5, CD19, CD20 and faint monotypic SIg. The MZL
cells were CD5-, CD19+ and CD20+. Mononuclear cells
were separated by Ficoll-Hypaque density centrifugation
(Lymphoprep™, Fresenius Kabi Norge AS, Oslo, Norway),
washed twice with PBS and then cell pellet was resus-
pended in RPMI-1640 culture medium.
Effect of TW-37 on Growth of established cell lines and 
fresh lymphoma cells
Cells from established lines (above) were plated in 24-
well culture clusters (Costar, Cambridge, MA) at a density
of 2 × 105 viable cells/ml/well. Triplicate wells were
treated with 0.0–750 nM TW-37. Plates were incubated at
37°C in a humidified incubator with 5% CO2. All cultures
were monitored throughout the experiment by cell count
and viability every 24 hr for 72 hr using 0.4% trypan blue
stain (Gibco BRL, Grand Island, NY) and a hemacytome-
ter. Fresh primary lymphoma cells isolated from patients
were processed similarly except cells were seeded at a den-
sity of 5 × 105/ml/well. Statistical analysis was performed
using the t test, two-tailed, with 95% confidence intervals
between treated and untreated samples. P value < 0.05
were used to indicate statistical significance.
Acridine orange/ethidium bromide (AO/EB) assay for 
apoptosis
After exposure to various concentrations of TW-37 for 48
or 72 hr, cells were collected by centrifugation and resus-
pended into 25 μl of PBS. One microliter of AO/EB mix
was added to each sample prior to analysis by fluorescent
microscope. Using fluorescence microscope, cells seen in
orange or light orange were counted as apoptotic whereas
cells in green or light green were counted as viable [24].
Data analysis was done using "GraphPad Prism 4.03"
software.
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Bcl-2 family protein expression profiling, caspase and 
PARP cleavage assays by Western blots
Bcl-2 family protein expression profile without TW-37
treatment among 4 WSU lymphoma cell lines was deter-
mined as baseline as previously described [25]. Cells were
seeded and cultured in T-75 cell culture flasks and har-
vested at exponential growth phase. Cells were lysed by
buffer containing 50 mM Tris-HCL, 1% NP-40, 0.1% SDS,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4
and protease inhibitor and total protein quantification
determined using Protein Assay (BioRad, Hercules, CA).
For Western Blotting, 40 or 100 μg of total protein was
separated by 12% or 15% SDS-PAGE gel electrophoresis
then transferred to nitrocellulose membrane (BioRad,
Hercules, CA). Membranes were blocked with 5% Fat Free
Dry Milk and subjected to immunoblotting using anti-
bodies against individual human Bcl-2 family proteins
[Pro-Apoptosis Bcl-2 Family Antibody Sampler Kit or Pro-
Survival Bcl-2 Family Antibody Sampler Kit (Cell Signal-
ing Technology, Beverly, MA)] at 4°C overnight with agi-
tation. After 3 washings, of 15 min each, membranes were
blotted with horseradish peroxidase HRP-conjugated sec-
ondary antibody at room temperature for 2 hr. Following
3 washings of each membrane, protein was detected by
ECL Western blotting detect reagent (GE Healthcare, Pis-
cataway, NJ). Fresh patient samples were analyzed by the
same method. All membranes in each experiment were
stripped, blocked and further immunoblotted with anti-β-
actin (Santa Cruz, Santa Cruz, CA) antibody to confirm
equal loading and as reference for quantification of Bcl-2
family protein expression level among each cell line and
sample. Expression level of each Bcl-2 family protein was
determined by scanning band density using "AlphaE-
aseFC" software and normalized to density of the β-actin
band of same sample and the quantification of the Bcl-2
family protein inventory, relative to β-actin, was tabu-
lated. Similar procedures were used for TW-37 or TW-37a-
treated cells and to detect caspase 3, 8, 9 and PARP cleav-
age using appropriate antibodies (Cell Signaling Technol-
ogy, Beverly, MA).
Caspase luminescent activity assay
Cells were seeded on white Luminometer 96-well plate
(Fisher Scientific, Hanover Park, IL) at 2 × 104 cells per
100 μl/well with various concentrations of TW-37 or 300
nM of TW-37a and cultured at 37°C, 5% CO2. Caspase
activity assay was performed after 4, 8, 2 and 24 hr of
treatment using Caspase-Glo3/7 Assay and Caspase-Glo 9
Assay kit (Promega, Madison, WI). Assay procedure was
done following manufacture's instruction using culture
media without cells as blank control. One hundred μl of
pre-mixed Caspase-Glo mixture was added to each assay-
ing well with shake at 300 rpm for 30 seconds then incu-
bated at room temperature protected from light for 1 to 3
hr. Luminescence was measured by Tecan Multifunction
microplate reader at OD450 nm versus OD595 nm. Data
was normalized by substituting substrate with blank con-
trol and analyzed by "GraphPad Prism 4.03" software.
Statistical analysis was done using two-tailed t-test.
Apoptotic DNA fragmentation assay
WSU-DLCL2 and WSU-FSCCL cells were exposed to TW-
37 or its trimethylated enantiomer (TW-37a) for 24 and
48 hr. 4 × 106 cells were harvested from each condition
and subsequently analyzed for DNA fragmentation using
Apoptotic DNA Ladder Kit (Roche, Indianapolis, IN).
DNA extraction procedure was done following manufac-
turer's instruction. DNA ladder was visualized by UV spec-
trometer after 1% agarose gel electrophoresis.
Co-immunoprecipitation of complexes and Western blot 
analysis
WSU-FSCCL cells were exposed to 1 or 2 μM TW-37 or
TW-37-A for 24 hr then lysed in buffer containing 50 mM
Tris·HCL, 1% CHAPS, 0.1% SDS, 150 mM NaCL, 1 mM
EDTA, 1 mM PMSF, 1 mM Na3VO4 and protease inhibitor.
300 μg of total protein from each lysate was subjected for
immunoprecipitation anti-Bim (Calbiochem, Darmstadt,
Germany) in a total volume of 200 μl at 4°C with agita-
tion. Supernatant was detected by Western blot with anti-
Bim, anti-BclXL (Calbiochem, Darmstadt, Germany) or
anti-Mcl-1 (BD Biosciences, San Diego, CA) antibody and
further detected with anti-Actin antibody (Santa Cruz,
Santa Cruz, CA).
SCID-mouse xenografts
Four-week-old female ICR-SCID mice were obtained from
Taconic Laboratory (Germantown, NY). The mice were
adapted for several days and WSU-DLCL2 xenografts were
developed as described previously [26]. Each mouse
received 107 WSU-DLCL2 cells (in serum-free RPMI-1640)
subcutaneously (SC) in each flank area. When SC tumors
developed to approximately 1500 mg, mice were eutha-
nized, tumors dissected and mechanically dissociated into
single-cell suspensions. Mononuclear cells were separated
by Ficoll-Hypaque density centrifugation and washed
twice with RPMI-1640 medium. These cells were sub-
jected to phenotypic analysis for comparison with the
established tumor cell line to insure the human origin and
its stability. After formation of SC tumors, serial propaga-
tion was accomplished by excising the tumors, trimming
extraneous materials, cutting the tumors into fragments of
20 to 30 mg that are transplanted SC using a 12 gauge tro-
car into the flanks of a new group of mice.
Efficacy trial design for TW-37
The maximum tolerated dose (MTD) for TW-37 is defined
as the dose that will lead to no deaths of any of the ani-
mals and no more than 10% loss of body weight during
treatment, followed by weight gain. To test the efficacy of
Journal of Hematology & Oncology 2009, 2:8 http://www.jhoonline.org/content/2/1/8
Page 4 of 13
(page number not for citation purposes)
TW-37 in vivo, small fragments of WSU-DLCL2 xenograft
were implanted SC bilaterally into naïve SCID mice as
previously described. Mice were checked three times per
week for tumor development. Once transplanted WSU-
DLCL2 fragments developed into palpable tumors (60–
100 mg), groups of five animals were removed randomly
and assigned to receive TW-37 or diluent (as control).
Mice were observed for measurement of SC tumors,
changes in weight and side effects of the drug. SC tumors
were measured three times per week.
Assessment of Tumor Response
The end-points for assessing anti-tumor activity were
according to standard procedures used in our laboratory
and are as follows: Tumor weight (mg) = (A × B2)/2, where
A and B are the tumor length and width (in mm), respec-
tively; Tumor growth inhibition (T/C) is calculated by
using the median tumor weight in the treated group (T)
when the median tumor weight in the control group (C)
reached approximately 900 mg. Tumor growth delay (T-
C) is the difference between the median time (in days)
required for the treatment group tumors (T) to reach 900
mg and the median time (in days) for the control group
tumors (C) to reach the same weight and tumor cell kill
(log10) total = (T-C)-/(3.32)(Td).
All studies involving mice were performed under Animal
Investigation Committee (AIC)-approved protocols.
Tumor weights in SCID mice were plotted against time on
a semi-log sheet with the growth pattern resembling an S-
shape. Tumor doubling (Td) is the time (in days) required
in order for the tumor to double its weight during the
exponential growth phase.
Statistical analysis
For the comparison of tumor weight, the power to detect
differences in the mean tumor weight at the completion of
treatment between treatment and control groups has been
calculated based upon a sample of 5 mice/10 xenografted
tumors per group. Power calculations assume that the use
of a two-sided, two-sample, t-test, with equal variance,
and assuming the difference between means to be a pro-
portion of the standard deviation of the outcome meas-
urement. For example, a 1-unit difference between groups
represents a difference of one standard deviation between
groups. The study has at least 90% power to detect differ-
ences larger than 1.6 units of standard deviation between
groups.
Results
Effect of TW-37 on growth of established malignant 
lymphoid cell lines and patient-derived lymphoma cells
The structure of TW-37 is given in Figure 1. The cell lines
selected span the spectrum of the B-cell lineage. In addi-
tion, fresh peripheral blood samples of patients with CLL
or leukemic phase of NHL were obtained under IRB-
approved protocol. In each case, cells were exposed to TW-
37 and TW-37a over 72 hr, and cell viability was deter-
mined. In general, exposure to TW-37 resulted in a dose-
dependant inhibition of cell proliferation. The TW-37
concentration resulting in 50% growth inhibition (IC50)
of the established cell lines (Fig. 1A) were as follows:
WSU-pre-B-ALL 180 nM (A.1); WSU-DLCL2 300 nM
(A.2); WSU-FSCCL 165 nM (A.3); WSU-WM 320 nM
(A.4). We have similarly tested growth inhibitory effect of
TW-37 on 8 patient samples (pt) obtained from 7
patients. Patients 1–6 have a diagnosis of CLL/SLL
whereas patient-7 has a diagnosis of marginal zone lym-
phoma (MZL). Two samples were obtained from case #6;
one before therapy (pt.6a), and the second (pt.6) while
the patient was on therapy with Rituximab and pred-
nisone. None of the other patients were under active ther-
apy at the time of obtaining blood samples except pt.2
who was receiving pulse dose chlorambucil and pred-
nisone. There was no significant increase in cell numbers
of control cultures after 72 hr; however, TW37-treated cul-
tures showed progressive decrease in cell numbers, which
was dose dependent (Fig. 1B). This was true of all patient
samples although the effect was less profound in cells
from pt.2 and pt.6 who were under treatment with chem-
otherapy for CLL/SLL. The inactive congener TW-37a had
no effect (data not shown). Moreover, TW-37 had no
effect on normal PBL (Fig. 1C).
TW-37 activates the caspase pathway and induces 
apoptosis
Since TW-37 targets proteins in the apoptotic pathway; we
investigated its ability to induce apoptotic cell death in
lymphoid cell lines and patients samples:
Apoptosis
TW-37 induced significant apoptosis in the cell lines and
fresh patient samples (Fig. 2). This effect was specific since
there was significant difference between TW-37 and TW-
37a used under the same conditions. The highest propor-
tion of cells in apoptosis was observed in WSU-FSCCL
indicating higher sensitivity to TW-37 whereas the lowest
was in WSU-WM (Fig. 2A). Similarly, TW-37 induced
apoptosis on each of the three patient samples examined
(Fig. 2B) with lower values in pt.2 that also showed less
growth inhibition (Fig. 1B). Interestingly, the Bax-to-Mcl-
1 ratio positively correlated with induction of apoptosis in
the cell lines and in the 2 fresh cases studied (R2 = 0.9682
and 0.9653 after 48 and 72 h of exposure to TW-37,
respectively, Figure 2C).
Caspase activation, PARP cleavage and DNA 
fragmentation
Exposure of WSU-FSCCL cells to TW-37 induced activa-
tion of caspase 9 and caspase 3 activity and PARP cleavage
Journal of Hematology & Oncology 2009, 2:8 http://www.jhoonline.org/content/2/1/8
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(Fig. 3A.1). Using luminescent assay, Caspase activation
was evident within 24 hr (Fig. 3A.2) and became more
pronounced with longer incubation. Caspase 3 and 9 acti-
vation was evident as early as 4 hr after exposure to TW-
37, which was again specific to TW-37. There was no acti-
vation of caspase 8. TW-37 also induced caspase 3 and 9
activation on WSU-DLCL2 cells (Fig. 3B.1). To confirm
induction of apoptosis, there was clear evidence of DNA
fragmentation of extracts from both WSU-FSCCL and
WSU-DLCL2 cells (Fig. 3A.3 and 3B.2).
Baseline expression of Bcl-2 family proteins in cell lines 
and fresh lymphoma cases
To determine if certain Bcl-2 family protein expression
profiles are associated with increased susceptibility to TW-
37, we determined the expression of major proteins in this
family in all 4 cell lines and 5 of the fresh cases using
Western Blotting analysis (Fig. 4). In all cases, fresh and
cell lines, cells expressed at least 2 of the 3 anti-apoptotic
proteins examined (Bcl-2, Bcl-XL, and Mcl-1). Bcl-2 was
over-expressed in all fresh cases, and cell lines except the
WSU-WM (expressed low levels), Bcl-XL was expressed in
all patient cells and cell lines (except WSU-ALL cell line)
and Mcl-1 was low only in WSU-ALL, WSU-DLCL2 and
pt4. There was variation in the expression of the pro-apop-
Structure of small molecule inhibitor TW-37Figure 1
Structure of small molecule inhibitor TW-37. Growth inhibition effect of TW-37 on 4 NHL cell lines and fresh cells 
obtained from 8 patient samples. Data represent IC50 at 72 hr from TW-37 exposure using trypan blue exclusion method. A) 
WSU-pre-ALL cell line (A1); WSU-DLCL2 cell line (A2); WSU-FSCCL cell line (A3) and WSU-WM cell line (A4). Cell lines 
were seeded in 24-well culture clusters at a density of 2 × 105 viable cells/ml per well. Triplicate wells were treated with 0.0–
750 nM TW-37 and incubated for up to 72 hr. B) Fresh patient derived cells were seeded in 24-well culture clusters at a den-
sity of 5 × 105 viable cells/ml per well. Triplicate wells were treated with 0.00–750 nM TW-37 and incubated for 72 hr. Cyto-
toxic effect of TW-37 on primary NHL cells is at 72 hr. C) Cytotoxic effect of TW-37 on normal peripheral blood 
lymphocytes was assayed by seeding 4 × 105 viable cell/ml and treated with 0.00–800 nM of TW-37 for up to 72 hr.
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totic proteins examined. In every case there was at least 3
pro-apoptotic proteins expressed.
Bcl-2 family protein of TW-37-Treated cells
In general Western Blot analysis conducted on all 4 cell
lines exposed to different concentrations of TW-37 at var-
ious time points showed no major changes in Bcl-2 family
protein levels (Fig. 5A–D). There was apparent increase of
Mcl-1 in WSU-pre-B-ALL cell line at 24 and 48 hr (Fig. 5A)
but similar finding was not seen in other cell lines (Fig.
5B–D). Similarly, Bcl-XL was more abundantly expressed
in WSU-DLCL2 after exposure to TW-37 for 72 hr (Fig. 5B)
but the finding did not extend to other cell lines. The fail-
ure of drug treatment to induce consistent change in the
steady-state level of Bcl-2 family proteins implies that
baseline (i.e., not drug treated) quantitation of these pro-
teins closely approximates the quantitation in drug-
treated cells, at least over the 48 to 72 hr interval.
TW-37 blocks hetrodimerization between pro- and anti-
apoptotic Bcl-2 family proteins
Protein lysates of TW-37-treated WSU-FSCCL cells were
immunoprecipitated with antibody to Bim BH3-only
proapoptotic protein. Immunoprecipitates were separated
Acridine orange/ethidium bromide (AO/EB) staining showing apoptosis induction by TW-37Figure 2
Acridine orange/ethidium bromide (AO/EB) staining showing apoptosis induction by TW-37. A, Apoptosis induc-
tion of TW-37 on 4 WSU-cell lines was assayed after 72-h exposure. WSU cell lines were seeded and treated with 500 nM of 
TW-37 and with inactive congener TW-37a [designated as "(-)"] in triplicate and apoptosis was determined by AO/EB staining 
after 72 h. B, Apoptosis induction of TW-37 on patient-derived NHL cells was determined on 3 selected samples. Apoptotic 
cells were assayed by AO/EB staining after exposure of TW-37 with concentrations ranging from 0 to 750 nM (0 is the same as 
TW-37a). C, Bax-to-Mcl-1 ratio positively correlates with induction of apoptosis by TW-37. The Bax/Mcl-1 ratio was plotted 
on the abscissa against this AO/EB metric on the ordinate for four cell lines (the filled diamonds represent 48 h and the empty 
squares represent 72 h treatments). Each line is calculated by linear regression using equal weighting of the four points; the 
lines described closely emanate from the origin (x-intercept = 0.046 to 0.084). Patient data (Patients-1 and 3, empty triangles) 
lie close to the lines fitted to the data for the four established NHL cell lines.
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by SDS-PAGE and electroblotted to a membrane. Subse-
quent immunoblotting with Mcl-1 and Bcl-XL revealed a
decrease in Bim-Mcl-1 and Bim-Bcl-XL complexes in the
WSU-FSCCL-treated cells compared with untreated (con-
trol) cell lysates (Fig. 6). The blocking of Bim-Mcl-1 het-
erodimerization is evident at 1 μM TW-37 and increased
at 2 μM; the blocking of Bim-Bcl-XL heterodimerization is
evident only at the highest drug concentration. This find-
ing confirms the ability of TW-37 to block Bim-Mcl-1 and
Bim-Bcl-XL heterodimerization. Using similar technique,
previously we have shown that TW-37 blocks Bid-Bcl-2
and Bid-Mcl-1 but not Bid-Bcl-XL in WSU-DLCL2 cell
lysate [27].
In vivo efficacy of TW-37 in WSU-DLCL2-SCID mouse 
xenografts
The MTD of TW-37 in SCID mice was determined to be
120 mg/kg when given alone as intravenous (iv) injec-
tions (40 mg/kg daily × 3 doses). Animals at this dose
experienced weight loss of < 5% and had scruffy fur, how-
ever with full recovery 48–72 hours after completion of
treatment.
Antitumor activity of TW-37 at its MTD against WSU-
DLCL2-bearing SCID mice as measured by tumor growth
inhibition (T/C), tumor growth delay (T-C) and log10kill
was 28%, 10 days and 1.5, respectively (Table 1). A T/C
Cleavage of caspase 9, 3 and PARP protein and induction of Caspase 3, 9 activity and resulting DNA fragmentation in TW-37 treated lymphoid c ll linesFigure 3
Cleavage of caspase 9, 3 and PARP protein and induction of Caspase 3, 9 activity and resulting DNA fragmen-
tation in TW-37 treated lymphoid cell lines. A) WSU-FSCCL cells were exposed to TW-37 (0 to 750 nM) at 24, 48 and 
72 hr. Caspase 3, 9, 8 and PARP protein cleavage was detected by Western blot (3A.1). Or cells were treated with TW-37 at 
0, 250 and 500 nM on white 96-well plate for 4, 8, 12 and 24 hr. Caspase 3, 9 activities were determined by Luminescence 
immediately on 96-well plate (3A.2). WSU-FSCCL cells treated with TW-37 at 250 and 500 nM. DNA fragmentation was seen 
evident after 48 hr (3A.3). (3B1.) Caspase 9 and 3 enzyme activation by TW-37 was also determined using WSU-DLCL2 lym-
phoid cell line. Cells exposed to 300, 400 nM of TW-37 for 4 or 8 hr, caspase 9 and 3 activity was detected. (3B.2) WSU-
DLCL2 cells treated with TW-37 at 500 and 750 nM, DNA fragmentation was evident after 48 hr.
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value of 42% or less is considered significant anti-tumor
activity by NCI, the drug evaluation branch of the division
of cancer treatment. Therefore, TW-37 is considered active
against WSU-DLCL2 tumor and resulted in significant
growth delay (p ≤ 0.01) compared with control (Fig. 7).
Discussion
B-cell tumors are a very heterogeneous group of diseases
with diverse clinical presentations, genetic anomalies,
phenotypes and natural histories [28-30]. Chemotherapy-
based regimens remain the cornerstone of treating B-cell
tumors but with varying results, underscoring the hetero-
geneity of this group of diseases despite their common B-
cell lineage. It is important, therefore, that any new thera-
peutic strategy be evaluated across the spectrum of these
tumors. This is especially important in targeted therapy of
selective intracellular molecular pathways. In this study,
we examined the activity of TW-37, a non-peptidic small-
molecule inhibitor of pan Bcl-2 family proteins, against
established human B-cell tumor lines and fresh patient
samples representing the spectrum of B-cell tumors in
man. Our results demonstrate activity of TW-37 across all
B-cell tumors irrespective of their proliferative status,
genetic abnormalities, and state of differentiation. The
study also reveals the ubiquitous expression of the Bcl-2
proteins and their complexity in B-cell tumors.
Our results presented here, show that small-molecule
inhibitors of the Bcl-2 family proteins has a therapeutic
role in a wide spectrum of B-cell tumors. All four cell lines
chosen in this study are highly proliferative, whereas the
fresh patient samples have low proliferation. TW-37 was
able to slow the growth of cell lines and increase the fre-
quency of apoptotic cells in fresh patient cultures (Fig. 1).
Inventory of Bcl-2 family protein by Western-blot quantification of anti-, pro-apoptotic Bcl-2 family protein of 4 NHL cell lines (4.A) and 5 fresh patient derived sampl s (4.B)Figure 4
Inventory of Bcl-2 family protein by Western-blot quantification of anti-, pro-apoptotic Bcl-2 family protein of 
4 NHL cell lines (4.A) and 5 fresh patient derived samples (4.B). Cells were harvested and lysed for Western-blot 
analysis. Forty μg of total lysate was subjected to detect multi-domain anti-apoptotic proteins Bcl-2, Bcl-XL and Mcl-1 proteins 
in NHL cell lines and patient derived samples. 80 μg of total cell lysate was loaded to detect multi-domain pro-apoptotic and 
BH3-only Bax, Bak, Bok, Bad, Bim and Puma profiles in WSU cell lines and patient-derived fresh samples.
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Selectivity of TW-37 toward tumor cells is demonstrated
by its lack of effect on normal peripheral blood lym-
phocytes (Fig. 1C). Such findings indicate that the TW-37
effect, and perhaps the class it represents, is not dependent
on the proliferative status of B-cell tumors. The IC50 of
TW-37 for the cell lines ranged between 165 nM and 320
nM (Fig. 1A). In the fresh cases, the IC50 ranged from 300
nM to1000 nM (Fig. 1B). However, it is important to note
that 1000 nM is still considered much more potent com-
pared to most standard anticancer therapeutic drugs. It is
interesting that the least sensitive (or resistant) cells (IC50
~1000) came from patients that were either under treat-
ment (Pt. 6) or whose disease has progressed after treat-
ment (Pt. 2) suggesting a possibility of cross resistance to
this modality. In support of this conclusion is the obser-
vation that fresh cells from patient #6, which were
obtained prior to therapy (Pt. 6A), showed more sensitiv-
ity to TW-37.
Bcl-2 was first discovered in association with the t(14;18)
translocation seen in the majority of follicular lympho-
mas [31] and is believed to play a pivotal role in follicular
lymphomagenesis. However, expression of Bcl-2 family
proteins is ubiquitous in B-cell tumors and does not
depend on t(14;18) or any other chromosomal transloca-
tions. All cases examined in this series including fresh
samples and established cell lines expressed one or more
protein in each class (Fig. 4). Over-expression or dysregu-
lation of the Bcl-2 proteins is perhaps another common
unifying theme among all B-cell tumors, which can be
exploited for therapy. In this study we have demonstrated
that TW-37 induces apoptosis in both patient-derived
lymphoma cells and established cell lines (Fig. 2). Expo-
Effect of TW-37 on the protein expression of Bcl-2, Bcl-XL, Mcl-1, Bax, Bim and β-actin was detected in 4 WSU cell lines, A) WSU-pre-B-ALL, B) WSU-DLCL2, C) WSU-FSCCL and D) WSU-WM cell lines after exposur  to 250, 500 or 750 nM of TW-37 or its inactive e antiomer TW-37a for 24, 48 or 72 h, cells were h rv sted, lysed and analyz d by western blot ana ysis with indi ated antibodiesFigure 5
Effect of TW-37 on the protein expression of Bcl-2, Bcl-XL, Mcl-1, Bax, Bim and β-actin was detected in 4 WSU 
cell lines, A) WSU-pre-B-ALL, B) WSU-DLCL2, C) WSU-FSCCL and D) WSU-WM cell lines after exposure to 
250, 500 or 750 nM of TW-37 or its inactive enantiomer TW-37a for 24, 48 or 72 h, cells were harvested, lysed 
and analyzed by western blot analysis with indicated antibodies.
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sure of fresh lymphoma cells and established cell lines to
TW-37 was associated with activation of caspase 3 and 9,
cleavage of the polyadenosine ribose polymerase (PARP)
into active fragments and DNA fragmentation (Fig. 3).
These are the hallmarks of mitochondrial dependent
intrinsic pathway of apoptosis [32]. Western Blot analysis
conducted on all lymphoma cell lines exposed to different
concentrations of TW-37 at various time points did not
show dramatic decrease or increase in the anti- and pro-
apoptotic proteins (Fig. 5A–D). These observations are
consistent with the presumed mechanism of TW-37
action as a BH3 mimic to interfere anti- and pro-apoptotic
Bcl-2 family protein interaction rather than interfere Bcl-2
family protein expression or stability and that small mol-
ecule inhibitor disrupts function but does not affect tran-
scription of Bcl-2 family proteins. It has been suggested
that the mechanism of TW-37-induced apoptosis is the
blocking of heterodimerization between anti-apoptotic
members, like Bcl-2, Bcl-XL, and Mcl-1, and pro-apoptotic
members like Bax and Bak of the Bcl-2 family [33]. Our
demonstration that TW-37 was able to block heterodimer-
ization between Bim and Bcl-2 as well as Bim and Mcl-1
(Fig. 6) lends support to this mechanism.
There are other BH3-mimetic SMIs now in clinical trials,
including ABT-737 [34] and GX15-070 [13]. However,
TW-37 is unique in its ability to target Mcl-1 (Fig. 6). It
was recently found that Mcl-1 expression is a key determi-
nant of resistance to ABT-737 [34,35]. Mcl-1 normally acts
at critical 'windows' of cell proliferation, differentiation
and apoptosis [36]. Within lymphoma, Mcl-1 is expressed
more abundantly in large (centroblasts) than small cells
(centrocytes) [37] and its expression is associated with
higher proliferation and worse prognosis [38]. In a study
of the molecular mechanism of the DNA damage
response during adenoviral infection, Cuconati et al. iden-
tified Mcl-1 as the key mediator [39]. Together, these stud-
ies highlight a role for Mcl-1 which was previously
unrecognized. Using data from our Bcl-2 family proteins
in 4 established cell lines and 7 lymphoma patients, we
might be able to address some of the basic principles of
the hypothesis accounting for the balance of Bcl-2 family
proteins, namely, the rheostat hypothesis proposed by
Korsmeyer [40-42]. The hypothesis implies that it is the
difference between the camps (i.e., subtracting the sum of
all the pro-apoptotic regulators from the sum of all the
anti-apoptotic regulators). In our recent studies, we have
also concluded that the Bax:Mcl-1 ratio may govern the
response of lymphoma cells to BH3-mimetic small mole-
cule inhibitors such as TW-37 [43]. The Bax:Mcl1 ratio
might become a clinically-important molecular prognos-
ticator of tumor response to TW-37 since, in this study, it
Immunoprecipitation and western-blot analysis of heterodimerization interaction by TW-37 between anti-apoptosis and pro-apoptosis B l-2 family proteinsFigure 6
Immunoprecipitation and western-blot analysis of heterodimerization interaction by TW-37 between anti-
apoptosis and pro-apoptosis Bcl-2 family proteins. WSU-FSCCL cells were treated with 1 or 2 μM of TW-37 for 24 hr, 
lysed and 300 μg of whole cell lysate was immunoprecipitated with anti-Bim followed by Western-Blot with anti-Mcl-1, anti-
Bcl-XL, anti-Bim and anti β-actin.
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correlated positively with TW-37-induced apoptosis (fig-
ure 2C).
Results of in vivo animals studies show that TW-37 alone
is an active agent against WSU-DLCL2 lymphoma with
tumor growth inhibition (T/C) value of 28%, tumor
growth delay (T-C) of 10 days and log10kill of 1.50 (Table
1). Usually, a T/C value of ≤ 42% for an agent is consid-
ered active by NCI criteria. In the mouse model treatment
with TW-37 resulted in statistically significant (p ≤ 0.01)
delay in tumor growth when compared to control (Figure
7).
In conclusion, the use of small molecule inhibitors of pan
Bcl-2 is an effective way of inducing apoptosis in a wide
range of B-cell tumors in humans as well as WSU-DLCL2
bearing SCID mice.
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